EGFR and lung cancer: In contrast, the OS tended to be shorter in patients with minor EGFR mutations, but without statistical significance (median: 62.7 vs. 35.1 months, p = 0.636) (Supplementary Fig. 3c), again suggesting that the importance of EGFR-TKI duration for survival benefit in EGFR-mutated lung cancer (Supplementary Fig. 3d).